Danish Bavarian Nordic has risen sharply on the stock exchange after the outbreak of mpox. The company manufactures vaccines against the disease and after the fear of a new pandemic, several countries have ordered large quantities of vaccines.
On Thursday, the company released an interim report that gave an extra boost to the share since the company management raised the revenue forecast further to 5.3 billion Danish kronor for the full year 2024.
In just a few weeks, the share price has risen 50-60 percent.
